Novel therapeutic delivery for neurodegenerative diseases: Strategies to overcome CNS barriers

---

Review Article

Author Details : Rohit R Doke*, Tejas S Naik, Disha L Lamkhade, Tanaya S Bhise, Vikrant N Khokrale, Yuvraj B Gosavi

Volume : 11, Issue : 1, Year : 2023

Article Page : 1-8

https://doi.org/10.18231/j.jpbs.2023.001

Suggest article by email

Get Permission

---

Abstract

The incidence of central nervous system (CNS) diseases is expected to rise significantly due to increasing lifespan and changing population demographics. Among CNS diseases, neurodegenerative diseases (ND’s) entail a significant challenge since they frequently involve neuronal loss and age-related progressive deterioration in brain function. Although the mechanisms and pathogenesis of neuronal disorders including Parkinson's disease (PD), Alzheimer's disease, and Huntington's disease (HD) have been extensively studied, effective treatment strategies remain limited. Drug delivery to the CNS is particularly challenging and poses a significant obstacle in the management of neurodegeneration. The present review focuses on the challenges associated with neuronal disorders, especially concerning the delivery of macro molecules containing proteins and nucleic acid. Additionally, we highlight opportunities to enhance therapeutic delivery for the treatment of ND’s. As our understanding of the biological aspects of ND’s continues to grow, there is a growing potential for therapeutic interventions. Therefore, these delivery strategies play a vital role for the future transition of CNS therapies from research labs to clinical practices.

Keywords: Parkinson's Disease, Alzheimer's Disease, Huntington's Disease, barriers to CNS delivery, strategies to enhance CNS delivery, Nose to brain drug delivery

How to cite : Doke R R, Naik T S, Lamkhade D L, Bhise T S, Khokrale V N, Gosavi Y B, Novel therapeutic delivery for neurodegenerative diseases: Strategies to overcome CNS barriers. J Pharm Biol Sci 2023;11(1):1-8

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.